ICER Gives Allergan, Biohaven CGRP Inhibitors Slight Edge Over Lilly’s Reyvow
Executive Summary
ICER’s final report on new acute migraine treatments said the drugs are similarly beneficial when patients don’t respond to or can’t take triptans, but found Reyvow is not as cost effective as Ubrelvy and rimegepant.
You may also be interested in...
Pricing Could Help Lundbeck's Vyepti In Slow-Growing CGRP Market
After eptinezumab’s approval in the US, EVP Peter Anastasiou told Scrip it will take time to change migraine doctors’ prescribing habits, but he expects CGRP inhibitors to become mainstay preventative treatments. Vyepti’s list price is about $1,000 below its competitors’ launch prices.
Lilly, Allergan Beat Biohaven To Acute Migraine Market With Reyvow, Ubrelvy Launches
After DEA scheduling, Reyvow will be available at pharmacies soon with a list price of $640 for eight tablets. Allergan confirmed that its drug is at pharmacies and prescriptions are being filled.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.